ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,572.85
      0.10%
      US Tech 100
      19,964.00
      0.35%
      Dow Jones
      39,344.79
      -0.08%
      Brent Oil
      85.105
      -0.36%
      Bitcoin
      57,495.78
      1.39%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Vertex Pharmaceuticals Inc (VRTX)

      7. Vertex Pharmaceuticals Inc (VRTX) News

      VRTX

      Vertex Pharmaceuticals (VRTX)

      Vertex Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:VRTX
      DateTimeSourceHeadlineSymbolCompany
      01/09/202412:42PMBusiness WireVertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi ArabiaNASDAQ:VRTXVertex Pharmaceuticals Inc
      01/08/20244:56PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      01/07/20243:00PMBusiness WireVertex Provides Pipeline and Business Updates in Advance of Upcoming Investor MeetingsNASDAQ:VRTXVertex Pharmaceuticals Inc
      01/04/20244:17PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      01/02/202410:32AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      12/19/20234:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      12/18/20234:05PMBusiness WireVertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8NASDAQ:VRTXVertex Pharmaceuticals Inc
      12/15/20234:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      12/15/20234:23PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      12/15/20234:20PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      12/15/202312:51PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      12/15/20238:12AMBusiness WireVertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta ThalassemiaNASDAQ:VRTXVertex Pharmaceuticals Inc
      12/14/20238:30AMAllPennyStocks.comCompany Intersects SaltNASDAQ:VRTXVertex Pharmaceuticals Inc
      12/13/20234:27PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      12/13/20233:23PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      12/13/20232:46PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      12/13/202312:48PMDow Jones NewsEditas Medicine Strikes License Deal With Vertex Pharmaceuticals -- UpdateNASDAQ:VRTXVertex Pharmaceuticals Inc
      12/13/202310:49AMDow Jones NewsVertex Pharmaceuticals Up Over 8%, on Track for Record High Close -- Data TalkNASDAQ:VRTXVertex Pharmaceuticals Inc
      12/13/20239:49AMDow Jones NewsEditas Medicine Strikes License Deal With Vertex PharmaceuticalsNASDAQ:VRTXVertex Pharmaceuticals Inc
      12/13/20236:30AMBusiness WireVertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral NeuropathyNASDAQ:VRTXVertex Pharmaceuticals Inc
      12/11/20237:30PMBusiness WirePositive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and ExpositionNASDAQ:VRTXVertex Pharmaceuticals Inc
      12/08/20234:11PMDow Jones NewsBluebird Bio Shares Slide 41% on Black-Box Label, Higher Price for Sickle-Cell TreatmentNASDAQ:VRTXVertex Pharmaceuticals Inc
      12/08/202312:59PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRTXVertex Pharmaceuticals Inc
      12/08/202312:52PMBusiness WireVertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell DiseaseNASDAQ:VRTXVertex Pharmaceuticals Inc
      12/08/202311:46AMDow Jones NewsCRISPR, Vertex Get FDA OK of Casgevy Gene Therapy in Sickle-Cell DiseaseNASDAQ:VRTXVertex Pharmaceuticals Inc
      12/06/20234:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      12/06/20234:03PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      12/05/20234:14PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRTXVertex Pharmaceuticals Inc
      12/05/20234:01PMBusiness WireVertex Appoints Nancy Thornberry to its Board of DirectorsNASDAQ:VRTXVertex Pharmaceuticals Inc
      11/29/20232:55PMDow Jones NewsVertex Pharmaceuticals' Kalydeco Gets Expanded Use Authorization from Health CanadaNASDAQ:VRTXVertex Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:VRTX